{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:18:08Z","timestamp":1783487888035,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272699"],"award-info":[{"award-number":["82272699"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116871","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:00:50Z","timestamp":1780718450000},"page":"116871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial"],"prefix":"10.1016","volume":"243","author":[{"given":"Qiuzhong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-3237","authenticated-orcid":false,"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116871_bib1","first-page":"200","article-title":"Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine","volume":"70","author":"Gamboa","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116871_bib2","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116871_bib3","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-23-0876","article-title":"The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications","volume":"29","author":"Denu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116871_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"von Mehren","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116871_bib5","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0017","article-title":"Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116871_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cncr.21626","article-title":"Metastatic osteosarcoma","volume":"106","author":"Daw","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116871_bib8","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116871_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib10","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib11","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116871_bib12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116871_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","article-title":"Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial","volume":"15","author":"Cho","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116871_bib15","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116871_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116871_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib18","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1158\/1078-0432.CCR-22-0871","article-title":"Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma","volume":"28","author":"Liu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116871_bib19","doi-asserted-by":"crossref","first-page":"S1038","DOI":"10.1016\/j.annonc.2023.09.1160","article-title":"1931P Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study","volume":"34","author":"Lee","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105097","article-title":"Landscape of ultra-rare sarcomas: a nationwide study for epidemiology and prognosis","volume":"10","author":"Shimada","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116871_bib21","article-title":"Anlotinib: a novel targeted drug for bone and soft tissue sarcoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib22","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116871_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","article-title":"Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study","volume":"130","author":"Yang","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116871_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1078-0432.CCR-22-2897","article-title":"Preoperative neutrophil-to-lymphocyte ratio and a new inflammatory biomarkers prognostic index for primary retroperitoneal sarcomas: retrospective monocentric study","volume":"29","author":"Fiore","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116871_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ctrv.2015.10.003","article-title":"Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis","volume":"41","author":"Nishijima","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116871_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10147-017-1199-6","article-title":"Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma","volume":"23","author":"Kobayashi","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib27","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/cam4.3773","article-title":"Elevated peripheral absolute monocyte count related to clinicopathological features and poor prognosis in solid tumors: Systematic review, meta-analysis, and meta-regression","volume":"10","author":"Wen","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116871_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/MEG.0000000000001553","article-title":"Peripheral monocyte counts predict the clinical outcome for patients with colorectal cancer: a systematic review and meta-analysis","volume":"31","author":"Wen","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2026.116871_bib29","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1200\/JCO.2018.36.15_suppl.11503","article-title":"Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial","volume":"36","author":"Chi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib30","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pbc.25548","article-title":"Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group","volume":"62","author":"Kim","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2026.116871_bib31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114070","article-title":"Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials","volume":"148","author":"Cao","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2026.116871_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116871_bib34","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2026.116871_bib35","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116871_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib37","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116871_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41392-025-02173-3","article-title":"Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results","volume":"10","author":"Levy","year":"2025","journal-title":"Signal Transduct Target Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:48:59Z","timestamp":1783486139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["S0959804926006520"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116871","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116871"}}